Skip to content

Search

Time running out to prepare for flu season

People are being urged to ensure they've had their vaccination with the 'flu season expected to hit in Western Australia within weeks.

National Indigenous Immunisation Research Workshop

You are invited to register to attend the National Indigenous Immunisation Research Workshop 2013: lessons learnt and future directions Workshop.

Experts gather for Aboriginal Immunisation Workshop

Experts in Aboriginal infectious disease research are in Perth this week for the National Indigenous Immunisation Research Workshop (November 7-8).

The science of immunisation: Questions and answers

Common myths about immunisation have been laid to rest in a new booklet written by top immunologists and published by the Australian Academy of Science.

New vaccine could protect against more types of cancer-causing HPV

Trial of new vaccine that could provide women with additional protection against Human Papillomavirus (HPV) types known to cause cervical cancer.

Perth women needed for international cervical cancer study

Perth women are being invited to take part in a global study of an exciting new vaccine that could protect against cervical cancer

FluCAN - The Influenza Complications Alert Network

The main aim of the study is to provide timely surveillance data to public health authorities on severe influenza.

New meningococcal strains bring increased risk in WA

A new study has confirmed the changing pattern of meningococcal disease in Western Australia.

Vaccination

Vaccination is the injection of an inactivated bacteria or virus into the body. This simulated infection allows an individual's immune system to develop an adaptive immunity for protection against that type of illness. When a sufficiently large percentage of a population has been vaccinated, this results in herd immunity.

Understanding parental decisions to decline or delay infant RSV immunisation, nirsevimab, in Western Australia in 2024

In 2024, the government of Western Australia introduced 'nirsevimab', a monoclonal antibody offering protection from respiratory syncytial virus (RSV), for eligible infants. This study explores why parents of infants who were eligible to receive nirsevimab opted to decline or delay the immunisation.